The active conformation of plasminogen activator inhibitor 1, a target for drugs to control fibrinolysis and cell adhesion
about
Crystal structures of native and thrombin-complexed heparin cofactor II reveal a multistep allosteric mechanism.X-ray crystal structure of MENT: evidence for functional loop-sheet polymers in chromatin condensationAn overview of the serpin superfamilyDistal hinge of plasminogen activator inhibitor-1 involves its latency transition and specificities toward serine proteasesPlasminogen Activator Inhibitor-1 in Cancer: Rationale and Insight for Future Therapeutic TestingThe conformational activation of antithrombin. A 2.85-A structure of a fluorescein derivative reveals an electrostatic link between the hinge and heparin binding regionsTopography of a 2.0 Å structure of α1-antitrypsin reveals targets for rational drug design to prevent conformational diseaseHigh-resolution structure of the stable plasminogen activator inhibitor type-1 variant 14-1B in its proteinase-cleaved form: A new tool for detailed interaction studies and modelingStructural Basis for Recognition of Urokinase-type Plasminogen Activator by Plasminogen Activator Inhibitor-1Crystal Structure of Plasminogen Activator Inhibitor-1 in an Active Conformation with Normal Thermodynamic StabilityMechanistic characterization and crystal structure of a small molecule inactivator bound to plasminogen activator inhibitor-1Crystal structure of cleaved vaspin (serpinA12)The molecular interactions of heat shock protein 47 (Hsp47) and their implications for collagen biosynthesisIdentification of the disulfide bonds in the recombinant somatomedin B domain of human vitronectinPolymerization of plasminogen activator inhibitor-1.Epitope mapping for four monoclonal antibodies against human plasminogen activator inhibitor type-1: implications for antibody-mediated PAI-1-neutralization and vitronectin-binding.Partitioning of serpin-proteinase reactions between stable inhibition and substrate cleavage is regulated by the rate of serpin reactive center loop insertion into beta-sheet A.Collapse of a long axis: single-molecule Förster resonance energy transfer and serpin equilibrium unfolding.The molecular basis for anti-proteolytic and non-proteolytic functions of plasminogen activator inhibitor type-1: roles of the reactive centre loop, the shutter region, the flexible joint region and the small serpin fragment.A novel mode of polymerization of alpha1-proteinase inhibitor.Old dogs and new tricks: proteases, inhibitors, and cell migration.E. coli trp repressor forms a domain-swapped array in aqueous alcohol.Serpin Inhibition Mechanism: A Delicate Balance between Native Metastable State and Polymerization.Differentially expressed proteins in the blood serum of piglets in response to a diet supplemented with inulin.A mechanism for assembly of complexes of vitronectin and plasminogen activator inhibitor-1 from sedimentation velocity analysis.Crystal Structure of the Michaelis Complex between Tissue-type Plasminogen Activator and Plasminogen Activators Inhibitor-1.Structural similarity of the covalent complexes formed between the serpin plasminogen activator inhibitor-1 and the arginine-specific proteinases trypsin, LMW u-PA, HMW u-PA, and t-PA: use of site-specific fluorescent probes of local environmentSerpins in thrombosis, hemostasis and fibrinolysisBugs in the system.Unravelling the twists and turns of the serpinopathies.Twenty years of polymers: a personal perspective on alpha-1 antitrypsin deficiency.Extending the capabilities of targeted molecular dynamics: simulation of a large conformational transition in plasminogen activator inhibitor 1.Characterising the association of latency with α(1)-antitrypsin polymerisation using a novel monoclonal antibodyPolymerization of human angiotensinogen: insights into its structural mechanism and functional significanceStructural differences between active forms of plasminogen activator inhibitor type 1 revealed by conformationally sensitive ligands.Distinct encounter complexes of PAI-1 with plasminogen activators and vitronectin revealed by changes in the conformation and dynamics of the reactive center loop.A deletion mutant of vitronectin lacking the somatomedin B domain exhibits residual plasminogen activator inhibitor-1-binding activityMetals affect the structure and activity of human plasminogen activator inhibitor-1. I. Modulation of stability and protease inhibitionThe length of the reactive center loop modulates the latency transition of plasminogen activator inhibitor-1.Structural factors affecting the choice between latency transition and polymerization in inhibitory serpins.
P2860
Q24534965-2E3A647E-095A-4D75-97BB-8FF468DD35F8Q24550849-F9A68F92-4E3C-4A01-846D-3309CA29B9F6Q24684030-F69BCFDC-4AC8-4D73-AF94-122E2490D462Q24793473-4941EC8A-9751-4A8A-9FC1-AF33C454EB83Q26801060-86A0894B-6239-40C1-AEBB-A9CB6766DB54Q27622522-69DBCDB2-1DB9-4D2F-84D2-1D3C9D36EEA1Q27626230-8010B47F-AAFB-4D9F-8575-E41371F2D871Q27651791-A039073E-29E9-48A2-B1C7-1303E3BACF4FQ27666429-FDEFA53E-C5D9-4EF8-9EA7-C71F27FCEED9Q27670512-7F319931-0491-4B28-9076-7FFA41B9B897Q27680739-C9B9B6A0-97E0-4ED2-898E-8CBEA54F3A9FQ27702566-A2B5FE02-C474-45A1-8103-5A2954FDEE07Q28191029-2FEFCC3B-53A4-438E-AC90-216315976543Q28218295-88D41310-52DB-4CA3-99CA-6D8C09A0BFD1Q31645732-29EFEEAE-BAAB-49E3-80B1-05E7A9FD6965Q31944726-08BB0ECB-6AFD-46E5-BD12-0B6558133576Q33179776-CAB18463-39DD-40D4-8377-957279A21E30Q33609148-DFCB1439-F126-4232-9F35-0177DCA6BC06Q34584787-3CF173B4-5779-4351-8DEC-85FEC163BBE5Q35089590-0BEABD62-DE1C-4F1E-B4D5-9090DBB98757Q35167706-83DF52CF-7C25-415F-97E7-C66819CBC261Q35586311-ABBC2985-F704-4787-A33A-65D12F9EC8E4Q35706783-D49A6530-F091-4C05-86E0-652A3A3D7FDEQ35855563-93F15257-FE10-47F3-8AC8-C2228A4195ABQ36083029-0E2828F6-D89B-4A23-A477-08A1EF167E02Q36283476-30E71968-7E37-4D46-AC2F-78A21773FECDQ36639269-84C934CC-A507-4C93-8F23-3DE90F1EC812Q36884340-7F42A318-688B-41EA-AAD1-4A4E20D2619BQ37108455-26CED98E-EF1E-45A4-A4AA-B0D9D40AFA16Q37882046-8419E27E-6776-4BCB-BF55-78D5319C186CQ38092851-C0A7151E-F42A-4179-976F-D47895E17630Q38271704-F386B388-8922-4781-BA72-E41ED0380811Q38933451-E2FA5847-0CE0-457C-8B2A-A8786008BF9DQ39087063-E5907A53-49CB-4A33-BB3B-42F59B197195Q39599940-EFCBC553-3EB6-4CCC-83F0-116EF82F3DB0Q39722375-9F758EC5-3154-4B78-B1E5-6314D5840815Q39782880-B9CD046E-9FE5-4298-AE80-057B99229342Q41790954-D87845A3-2544-4139-8164-071C5BFEF00EQ41857439-4C311622-9D5C-4AFF-B6F3-55C2BD6F1644Q41869912-6BA3B97A-100E-4527-894E-BBD8C516F625
P2860
The active conformation of plasminogen activator inhibitor 1, a target for drugs to control fibrinolysis and cell adhesion
description
1999 nî lūn-bûn
@nan
1999 թուականի Փետրուարին հրատարակուած գիտական յօդուած
@hyw
1999 թվականի փետրվարին հրատարակված գիտական հոդված
@hy
1999年の論文
@ja
1999年論文
@yue
1999年論文
@zh-hant
1999年論文
@zh-hk
1999年論文
@zh-mo
1999年論文
@zh-tw
1999年论文
@wuu
name
The active conformation of pla ...... fibrinolysis and cell adhesion
@ast
The active conformation of pla ...... fibrinolysis and cell adhesion
@en
The active conformation of pla ...... fibrinolysis and cell adhesion
@nl
type
label
The active conformation of pla ...... fibrinolysis and cell adhesion
@ast
The active conformation of pla ...... fibrinolysis and cell adhesion
@en
The active conformation of pla ...... fibrinolysis and cell adhesion
@nl
prefLabel
The active conformation of pla ...... fibrinolysis and cell adhesion
@ast
The active conformation of pla ...... fibrinolysis and cell adhesion
@en
The active conformation of pla ...... fibrinolysis and cell adhesion
@nl
P2093
P50
P1433
P1476
The active conformation of pla ...... fibrinolysis and cell adhesion
@en
P2093
M B Berkenpas
R W Carrell
P304
P356
10.1016/S0969-2126(99)80018-5
P577
1999-02-01T00:00:00Z